Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001680 · ClinicalTrials.gov registry record · Phase 2
A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00001680: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00001680 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001680, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this double-masked, pilot trial is to determine whether 20 percent thalidomide ointment is safe and effective for the treatment of chronic discoid lupus erythematosus (CDLE) when used under an occlusive dressing. Seventeen patients with two similar lesions will have lesions randomized to receive either intervention or placebo therapy.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 1997-10 |
| Est. Completion | 2001-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001680
The ClinicalTrials.gov registry entry for NCT00001680 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT00001680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001680 about?
NCT00001680 is a clinical study titled "A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus". The purpose of this double-masked, pilot trial is to determine whether 20 percent thalidomide ointment is safe and effective for the treatment of chronic discoid lupus erythematosus (CDLE) when used under an occlusive dressing. Seventeen patients with two similar lesions will have lesions randomized...
What is the current status of trial NCT00001680?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 1997-10. Estimated completion is 2001-07.
What interventions are being tested in trial NCT00001680?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00001680?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.